各类恶性肿瘤患者血清免疫反应性胰腺磷脂酶A2
Serum immunoreactive pancreatic phospholipase A2 in patients with various malignant tumors.
作者信息
Oka Y, Ogawa M, Matsuda Y, Murata A, Nishijima J, Miyauchi K, Uda K, Yasuda T, Mori T
机构信息
Second Department of Surgery, Osaka University Medical School, Japan.
出版信息
Enzyme. 1990;43(2):80-8. doi: 10.1159/000468710.
The high incidence (40.6%) of elevated serum pancreatic phospholipase A2 (PLA2) was demonstrated in patients with various malignancies. Serum PLA2 was significantly increased in cancer patients compared with healthy sex- and age-matched blood donors (358.4 +/- 168.0 vs. 241.7 +/- 69.0 ng/dl; p less than 0.01). No correlation was observed between serum PLA2 and carcinoembryonic antigen (CEA) in these patients. Although patients with advanced and distantly metastatic cancer of the liver, gallbladder and pancreas showed higher PLA2 levels in serum than those with early cancer, patients with other cancers showed no correlation between serum PLA2 and clinical stage. A combined assay of PLA2 and CEA increased the sensitivity of detection of cancers to 60.8%.
各种恶性肿瘤患者血清胰腺磷脂酶A2（PLA2）升高的发生率较高（40.6%）。与年龄和性别匹配的健康献血者相比，癌症患者血清PLA2显著升高（358.4±168.0对241.7±69.0 ng/dl；p<0.01）。在这些患者中，未观察到血清PLA2与癌胚抗原（CEA）之间的相关性。尽管肝、胆囊和胰腺晚期及远处转移癌患者血清PLA2水平高于早期癌症患者，但其他癌症患者血清PLA2与临床分期之间无相关性。PLA2和CEA联合检测可将癌症检测的敏感性提高到60.8%。
Zotero 插件